These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Analysis of mRNA and Protein Levels of Di Maio A; De Rosa A; Pelucchi S; Garofalo M; Marciano B; Nuzzo T; Gardoni F; Isidori AM; Di Luca M; Errico F; De Bartolomeis A; Marcello E; Usiello A Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163460 [TBL] [Abstract][Full Text] [Related]
12. MicroRNA-144 is regulated by activator protein-1 (AP-1) and decreases expression of Alzheimer disease-related a disintegrin and metalloprotease 10 (ADAM10). Cheng C; Li W; Zhang Z; Yoshimura S; Hao Q; Zhang C; Wang Z J Biol Chem; 2013 May; 288(19):13748-61. PubMed ID: 23546882 [TBL] [Abstract][Full Text] [Related]
13. Surface expression and limited proteolysis of ADAM10 are increased by a dominant negative inhibitor of dynamin. Carey RM; Blusztajn JK; Slack BE BMC Cell Biol; 2011 May; 12():20. PubMed ID: 21586144 [TBL] [Abstract][Full Text] [Related]
14. Tetraspanin 3: A central endocytic membrane component regulating the expression of ADAM10, presenilin and the amyloid precursor protein. Seipold L; Damme M; Prox J; Rabe B; Kasparek P; Sedlacek R; Altmeppen H; Willem M; Boland B; Glatzel M; Saftig P Biochim Biophys Acta Mol Cell Res; 2017 Jan; 1864(1):217-230. PubMed ID: 27818272 [TBL] [Abstract][Full Text] [Related]
15. Dysregulated ADAM10-Mediated Processing of APP during a Critical Time Window Leads to Synaptic Deficits in Fragile X Syndrome. Pasciuto E; Ahmed T; Wahle T; Gardoni F; D'Andrea L; Pacini L; Jacquemont S; Tassone F; Balschun D; Dotti CG; Callaerts-Vegh Z; D'Hooge R; Müller UC; Di Luca M; De Strooper B; Bagni C Neuron; 2015 Jul; 87(2):382-98. PubMed ID: 26182420 [TBL] [Abstract][Full Text] [Related]
16. ADAM9 inhibition increases membrane activity of ADAM10 and controls α-secretase processing of amyloid precursor protein. Moss ML; Powell G; Miller MA; Edwards L; Qi B; Sang QX; De Strooper B; Tesseur I; Lichtenthaler SF; Taverna M; Zhong JL; Dingwall C; Ferdous T; Schlomann U; Zhou P; Griffith LG; Lauffenburger DA; Petrovich R; Bartsch JW J Biol Chem; 2011 Nov; 286(47):40443-51. PubMed ID: 21956108 [TBL] [Abstract][Full Text] [Related]
17. Effects of neuron-specific ADAM10 modulation in an in vivo model of acute excitotoxic stress. Clement AB; Hanstein R; Schröder A; Nagel H; Endres K; Fahrenholz F; Behl C Neuroscience; 2008 Mar; 152(2):459-68. PubMed ID: 18276079 [TBL] [Abstract][Full Text] [Related]
18. nELAV proteins alteration in Alzheimer's disease brain: a novel putative target for amyloid-beta reverberating on AbetaPP processing. Amadio M; Pascale A; Wang J; Ho L; Quattrone A; Gandy S; Haroutunian V; Racchi M; Pasinetti GM J Alzheimers Dis; 2009; 16(2):409-19. PubMed ID: 19221430 [TBL] [Abstract][Full Text] [Related]
19. ADAM10 missense mutations potentiate β-amyloid accumulation by impairing prodomain chaperone function. Suh J; Choi SH; Romano DM; Gannon MA; Lesinski AN; Kim DY; Tanzi RE Neuron; 2013 Oct; 80(2):385-401. PubMed ID: 24055016 [TBL] [Abstract][Full Text] [Related]
20. A novel blood-brain barrier co-culture system for drug targeting of Alzheimer's disease: establishment by using acitretin as a model drug. Freese C; Reinhardt S; Hefner G; Unger RE; Kirkpatrick CJ; Endres K PLoS One; 2014; 9(3):e91003. PubMed ID: 24608847 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]